E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with locally advanced or metastatic NSCLC (Stage IIIA, IIIB, or IV) that is not amenable to curative therapy. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029522 |
E.1.2 | Term | Non-small cell lung cancer stage IV |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to compare pemetrexed plus enzastaurin when given in a BID dosing schedule versus pemetrexed plus placebo BID in terms of the progression-free survival time (PFS) of patients receiving second-line therapy for the treatment of locally advanced or metastatic NSCLC. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are to assess and compare the following variables between treatment arms: time-to-event variables, including: - overall survival (OS) - time to worsening of symptoms (TWS) - duration of disease control (DDC) disease control (best response of stable disease [SD], partial response [PR], or complete response [CR]) tumor response (best response of partial response [PR], or complete response [CR]) the safety and adverse event profile (including Common Terminology Criteria for Adverse Events [CTCAE v3.0, NCI 2006] grades for laboratory and nonlaboratory adverse events) maximum improvement over baseline score for each item of the Lung Cancer Symptom Scale (LCSS) biomarkers relevant to enzastaurin, pemetrexed, the disease state, and the clinical outcome. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
[1] Histologic or cytologic diagnosis of NSCLC with locally advanced or metastatic disease (Stage IIIA, IIIB or IV at entry) that is not amenable to curative therapy per the American Joint Committee on Cancer Staging Criteria for Lung Cancer [2] Patients must have progressive disease after 1 prior systemic cytotoxic chemotherapy regimen for advanced disease. Prior chemotherapy given as neoadjuvant or adjuvant therapy for early stage disease, completed at least 12 months prior to the diagnosis of advanced stage disease, will not be counted as a prior regimen. Previous treatment with bevacizumab or other targeted agents is permitted, provided that the targeted agent was initiated concurrently with chemotherapy as part of first-line treatment. [3] At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines [4] Performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) performance status scale [5] Previous radiation therapy (including thoracic radiation) allowed to 25% of the bone marrow, but should have been limited and must not have included whole pelvis radiation. Patients must have recovered from the toxic effects of the treatment prior to enrollment (except for alopecia). Prior radiotherapy must be completed at least 2 weeks prior to enrollment. Lesions that have been irradiated cannot be included as sites of measurable disease unless clear tumor progression has been documented in these lesions since the end of radiation therapy. [6] Adequate organ function including the following: Adequate bone marrow reserve: white blood cell (WBC) count >=3.0 × 109/L, absolute neutrophil count (ANC) >=1.5 × 109/L, platelet count >=100.0 × 109/L and hemoglobin >=9.0 g/dL (>=5.6 mmol/L). Hepatic: bilirubin <=1.5 times the upper limit of normal (x ULN); alkaline phosphatase (ALP), aspartate transaminase (AST), and alanine transaminase (ALT) <=2.5 × ULN, or <=5 × ULN with liver metastases. Renal: serum creatinine <1.5 ULN and calculated creatinine clearance (CrCl) >=45 mL/min based on the standard Cockcroft and Gault formula [10] Written informed consent. |
|
E.4 | Principal exclusion criteria |
[1] Previous treatment with enzastaurin or pemetrexed. [2] Recent (within 30 days of enrollment) or concurrent yellow fever vaccination. [3] Serious cardiac condition, such as myocardial infarction within 6 months, angina, abnormal ECG indicative of cardiac disease, or heart disease, as defined by the New York Heart Association Class III or IV (see Protocol Attachment JCBT.8). Patients with a QTc prolongation >450 msec (males) or >470 msec (females) and patients who have a congenital long-QT-syndrome in their own medical history or family medical history should be excluded. [4] Central nervous system (CNS) metastases (unless the patient has completed successful local therapy for CNS metastases and has been off corticosteroids for at least 4 weeks before study enrollment). A screening computed tomography (CT) or magnetic resonance imaging (MRI) scan before enrollment, in the absence of a clinical suspicion of brain metastases, is not required. [5] Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose <= 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam). [6] Inability to discontinue use of carbamazepine, phenobarbital, and phenytoin (refer to Section 5.7). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression Free Survival |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |